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Three DNA restriction fragments designated tyrT, 102-mer and 70-mer, have been used as substrates for footprinting studies using DNase i in 
the presence of the structurally similar antibiotics chartreusin and elsamicin A. The sequence-selective binding sites of the antibiotics can be mapped 
in regions which are rich in guanine+cytosine. Chartreusin and elsamicin appear to recognize and bind preferentially to sequences containing a
CpG step. Regions containing a TpG step also seem to be a good binding site. The binding of elsamicin to these sites appears to be more 
concentration-dependent. A comparative analysis is performed of the sizes and locations of the different binding sites, aimed to infer whether the 
different biological effects of cbartreusin and elsamicin A can be correlated to differences in their sequence-selective binding to DNA. 
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1. INTRODUCTION 
Chartreusin and elsamicin A are two structurally re- 
lated antibiotics (see Fig. I) containing the common 
aglycone chartarin but different sugar moieties [I-4]. 
Although chartreusin is active against a number of 
mouse tumours [5] it is an improbable candidate for 
clinical trials because of its water insolubility and poor 
pharmacokinetic profile [3,5]. Elsamicin A, which is 
much more water-soluble especially under acidic condi- 
tions, is several times more potent in a number of 
murine tumours [2], and it is at present undergoing 
Phase I clinical trials [6]. 
Chartreusin (Fig. 1) is known to induce strand scis- 
sion in a reducing environment and to inhibit relaxation 
of negatively superhelical DNA [7,8]. Although direct 
interaction with DNA is believed to be central to the 
mechanism by which chartreusin acts [3,7,8], the in- 
vestigations aimed at detecting possible base-sequence 
selectivity in the binding of this antibiotic to DNA have 
yielded conflicting results [3]. It appears to bind 
cooperatively to A+T and G+C polymers but not to 
calf-thymus DNA, reflecting some affinity for alternat- 
ing pyrimidine-purine base pairs [3]. Resulting on the 
sequence-specific binding of elsamicin A (Fig. 1) to 
DNA are more scarce. It has been observed that elsa- 
micin produces extensive DNA breakage in intact cells 
but not in pure DNA in vitro [9]. The possible site or 
sequence specificity of the elsamicin-DNA interaction 
remains undefined. 
In order to clarify the sequence specificity of the 
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DNA interaction with chartreusin and elsamicin we 
have employed the techniqu~ of DNase I footprinting 
(reviewed in [10]) to locate the precise binding sites for 
both antibiotics. Our results provide the clearest exper- 
imental evidence to date that both chartreusin a d elsa- 
micin A recognize and bind preferentially to the se- 
quence CpG, most probably within a longer sequence, 
despite the differences found in their chemical structure 
(see Fig. 1). Nonetheless, ome differences are observed 
in the behaviour of the antibiotics and the size of the 
binding sites. 
2. MATERIALS AND METHODS 
2. I. Antibiotics 
Chartreusin (U-7257) was a gift from Dr. W.C. Krueger (The 
Upjohn Co., Kalamazoo. USA). Elsamicin A (BMY-28090) was 
kindly provided by Bristol-Myers Co. (Wallingford, USA). l mM 
stock solutions of each antibiotic were prepared by direct weighing 
and dissolved in dimethylsulphoxide (DMSO). Fresh diluted solutions 
were prepared from the stocks diluted in I0 mM Tris-HCl, pH 7.5 
containing 10 mM NaCI. 
2.2. DNA substrates 
The 160-base pair tyrT fragment from E. coli (Fig. 2), containing 
a tRNA promoter, was isolated and labelled at the 3'-end of its lower 
(Crick) strand using reverse transcriptase nd [0~-32P]dATP [11-13]. 
The 102-rner and 70 base-pair fragments from pBR322 (Fig. 2), were 
cut out ~f the plasmid and labelled with [0t-~dP]dATP as described 
elsewhere [14,15]. 
2.3. DNase I Jbotprhsting 
Samples of the labelled DNA fragments (9 pmol in base pairs) were 
incubated with an appropriate antibi0tic solution, at 37°C for 30 rain, 
to give concentrations between I and 100,uM of chartreusin or elsa- 
micin A, so the final DMSO concentration was below 10%. These 
solvent concentrations do not alter the footprinting experiments sig- 
nificantly 116]. 
DNasc I was purchased from Boehringer Mannheim and prepared 
as a 7200 units/ml stock solution in 0.15 M NuCI containing 1 mM 
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MgCI:. It was stored at -20°C and diluted to working concentration 
immediately before us . 
DNasc I footprints were performed as previously described [12-14]. 
The products of the nuclease digestion were analysed on 0.3 mm 
polyacrylamide g ls (8% for the tyrT DNA fragment; 12% for the 
70-mer and 102-met) containing Tris-borate-EDTA buffer, pH 8.3.
2.4. Dimethyl sulphate modification 
After incubation fthe DNA fragments together with the antibio- 
tics, dimethylsulphate modification was performed basically as de- 
scribed in [16]. 
2.5. Densitometry and alysis 
Autoradiographs from the DNase I footprinting experiments were 
analysed using a Joyee-Loebl NR-III-CS microdensitometer to 
produce profiles from which the intensity ofeach band was measured. 
Band intensities were transformed into values for the fractional 
cleavage OO=A~IA,. where Ai is the area under band i and At is the sum 
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CHARTILEUSIN: Rt"-H; Rz--OH 
ELSAMICIN A: Rl = -CH~; R2- .NFI~* 
Fig. I. Chemical structures of chartreusin and elsamicin A. 
3. RESULTS 
Typical DNase I digestion patterns for the 160-base- 
pair tyrT DNA fragment in the presence of three differ- 
ent elsamicin concentrations and 30pM chartreusin are 
displayed in Fig. 3. Each gel lane contains about 100 
bands that can be satisfactorily resolved. The densito- 
metric analysis of  these bands produces the differential 
cleavage plots shown in Fig. 4. It is immediately ap- 
parent hat the cleavage pattern in the presence of both 
antibiotics is different from that of the DNA alone. 
Regions protected from digestion are readily apparent 
near positions 35, 55, 70, 95 and 115. It is also evident 
that the rate of cleavage at certain bonds is strongly 
enhanced compared with the control. 
We examined the effect on the digestion pattern of 
several antibiotic concentrations in the range between 
1 and 100 pM,  the patterns remained essentially con- 
stant for chartreusin, while it appears that elsamicin A 
concentrations higher than about 20/~M render slightly 
larger footprints and an increase, in all cases, in the 
extent of  the protection pattern as displayed in Fig. 4. 
Moreover,  a clear difference is observed, even at lower 
concentrations of  elsamicin, in some regions as for ex- 
ample around position 35 where the protected zone is 
always larger than for chartreusin. That  the chartreusin 
footprints are not as impressive as those of  elsamicin is 
somewhat puzzling and probably arises from diffe- 
rences in the binding characteristics of  the two com- 
pounds. Since these sites are more concentration de- 
pendent han the CG-zones (see Fig, 3) we think that 
they might represent a weaker binding site, since DNase 
I is considered to be a good probe to detect such binding 
tyrT DNA 
3'-JULGGCCAATTGGAAATTAGGCAATGCCTACTTTTAATGCGTTGGTCAAGTAAAAAGAGTTGCATTGTGAAATGTC 
Z0 20 30 40 50 60 70 
GCCGCGCAGTAARCTATACTACGCG~GAA~TRTTCCCTCGTCCGGTCATTTTTCGTAATGGGGCACCACC 





40 50 60 70 80 90 100 
102-mot fragment 
5t-,CTAAGAA~CCATTATTATCATGAC~TTAACCTATAAAA~TAGGCG~ATCACGAGGCCCTTTCGTCTTCAA 
4300 4310 4320 4330 4340 4350 
GAATTCTCATGTTTGACAGCTTATCATCGATAA- 3' 
4360 Z0 20 
Fig. 2. Sequenecs of the DNA fragments used in the footprinling experiments. Only the strand bearing the radioactive la0cl (outlined) is shown. 
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Fig. 3. DNas¢ I footpr int ing of elsamicin A (ELS: 5 pM,  15 pM and 
30/~M) and chartreusin (CHR: 30#M)  bound to the 160 bp duplex 
tyrT DNA (9 pmoI  in base pairs) whose sequence is shown in Fig, 2. 
Digestions were per formed for 2 rain. The Crick (bottom) strand is 
displayed. A track labelled G represents a dimethylsulphate-piper idinc 
marker specific for guanine. The samples were run together with at 
control  (C) to which no drug had been added. 
sites [10]. It is well known that a zone protected from 
DNase I attack cannot always be correlated in a 
straightforward manner with the real binding site size 
[17], However, because these differences are observed 
with two closely related antibiotics it is reasonable to 
suppose that a detailed analysis of tile protected regions 
can give clues on any difference between the sequence- 
selective binding sites for chartreusin and elsamicin A. 
In order to investigate the effects of chartreusin and 
elsamicin on DNA, as well as to gain more information 
to compare their binding sites, we performed further 
footprinting experiments using 70 and 102 base-pair 
fragments derived from pBR322. Illustrated in Fig. 5 
are electrophoretic patterns determined in the presence 
of each antibiotic. Differential cleavage plotscalculated 
from the data are represented in Fig. 6. Once again, 
clear regions of blockage are observed, which are even 
more apparent han on the tyrT DNA, for example 
around positions 4345 (102-mer) or 70 (70-mer). As for 
the tyrT DNA,  all these protected regions are mostly 
GC-rich, thus we can state with confidence that char- 
treusin and elsamicin bind to DNA regions containing 
G+C base pairs. The DNA region around the position 
50 in the 70-mer DNA is another clear example of the 
binding of elsamicin to TpG steps (Figs. 2 and 5), This 
region behaves as a weaker binding site for chartreusin. 
The size of the regions protected from DNase I cleavage 
ranges from a minimum of four base pairs (around 
position 105 in the tyrT DNA) a value near that of the 
exclusion parameter of chartreusin [3], to 11 base pairs 
(around position 40 in the same fragment). These values 
are even more impressive when the elsamicin concentra- 
tion is raised over 30 gM. We also found (data not 
shown) that the presence of chartreusin and elsamicin 
does not significantly alter the guanine-specific dime- 
thylsulphate-piperidine cleavage of the tyrT and 102- 
mer DNAs. Since this reaction is particularly sensitive 
to ligand blockage in the major groove, we conclude 
that chartreusin and elsamicin would probably interact 
with DNA throughout the minor groove, a common 
property displayed by most of the intercalating agents 
[10]. 
4. DISCUSSION 
Chartreusin and elsamicin A produce distinctly 
altered patterns of DNase I digestion (Figs. 3 and 5). In 
general, the regions protected by elsamicin from the 
enzyme attack are larger than those seen for char- 
treusin. The data presented in this paper provide the 
basis for a detailed comparison between the effects of 
the two antibiotics. The first, and main, conclusion is 
that they bind preferentially to(and protect from DNase 
I cleavage) regions containing adjacent guanine+cytosine 
base pairs. The precise sequence appears to be a pyri- 
midine-purine arrangement (probably CpG). Char- 
treusin and elsamicin A seem to present a less pro- 
nounced sequence specificity than other intercalators a  
"~, ~mycin D [13] or echinomycin [12]. The presence 
of a CG tract as a binding site for chartreusin is not at 
variance with a study performed using restriction en- 
zymes, which suggests that it binds to CGC regions [8]. 
A comparison of Figs, 3 and 5 shows that the binding 
sites are larger for elsamiein. Since the differences be- 
tween these antibiotics reside in the disaccharide moiety 
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3' ~Gnn~G~RCC~C~G~C~Tg~GGC~CC~-S'  
• II II • • 
I16 lZB 136 148 159 
3'-CG~TGGAnN~hGGCAATGC~nATGC~1G~A~nAN-$' 3' -¢¢C~ATG~AAn~NCGCnATGC~n~r~A~TGC~G~Cn~nAA-$' 
• ; ; . . . ; . . . 
18 Z 3 IB 58 IB ~ 30 4B 5B 
Fig. 4. Differential cleavage plots for the difference in susceptibility of the tyrT fragment (bottom strand) to DNase I attack in the presence of: 
30/.tM chartreusin (A), and 15/.tM elsamicin (B). The ordinate scale is in units of ln(/~,)-In~) where f~ is the fractional cleavage in a control 
experiment and ~ is the fractional cleavage of the same bond in the presence of antibiotic. Negative values on the ordinate indicate protection by 
the bound antibiotic, positive values indicate nhanced cleavage. 
(see Fig. 1) we tentatively considered that the sizes pos- 
sibly reflected that the binding site for elsamicin could 
be a quadruplet site to favour interactions between the 
charged amino sugar and the first base (of four) at the 
5'-end of the binding site. Alternatively, the extra hy- 
drogen bond might account for the binding ofelsamicin 
to TpG (possibly as 5'pyrTG3' triplets). Nevertheless, it 
could be considered that the larger footprints reflect a 
major distortion of the DNA substrate produced by 
elsamicin binding. An indirect way to detect he effect 
of bound ligands on the DNA structure is to consider 
the enhancements ob erved in the footprinting els and 
in the differential plots. The enhancements produced by 
elsamicin binding are more potent han those induced 
by chartreusin, yet the differences eem too small to 
conclude that the footprint sizes are a direct conse- 
quence of a bigger distortion of the DNA double helix 
after elsamicin binding. The clear concentration-de- 
pendent response produced by elsamicin in contrast 
with chartreusin was a surprise due to the similarity 
between both antibiotics (Fig. 1). A concentration-de- 
pendent pattern has been described for other DNA- 
binding drugs (see [14] and references there in). This is 
clearly related to the nature of the ligand but also 
depends upon the nature of the DNA molecule (cf. Figs. 
3 and 5). The concentration-dependence of the 
footprinting pattern is observed with the tyrT DNA (cf. 
Figs. 3 and 5) but it is more evident in other fragments 
as, for example, the 70-mer. 
It has been reported that chartreusin would bind 
cooperatively to poly[d(AT)].poly[d(AT)] and poly- 
[d(GC)].poly[d(GC)] but not to calf thymus DNA [3]. 
An explanation given to these results suggested a 2-3 
base-pair binding sites, with the antibiotic binding with 
high affinity to alternating AT and GC sites [3]. It is not 
possible to check the presence of cooperative binding, 
since the possibility of A+T or G+C protected sites 
appearing in long tracts is relatively small in the DNAs 
we have used in our footprinting study. Nonetheless, it 
is noteworthy that none of the AT-rich tracts found in 
these DNAs is significantly protected from DNase I 
cleavage. Unfortunately, no similar studies have been 
performed (to our knowledge) on the elsamicin binding 
to DNA polymers of different base-pair compositions, 
so we cannot compare our footprinting data in the same 
way. It is tempting to speculate whether the larger bind- 
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Fig. 5. DNase I footprinting of 30/aM chartreusin (CHR) and 15/aM elsamicin (ELS) on the 102-mer (AatlI-Hindlll) (A) and 70-mer (HindlII- 
Hhal) (B) fragments from pBR322. Each set of two tracks represents 1 rain and 5 rain digestion bythe enzyme. Other details as in legend to Fig. 
3. 
ing sites for elsamicin may reflect a cooperative be- 
haviour in at least some of the binding sites. Although, 
at present, this explanation cannot be ruled out, we are 
more inclined to believe that the larger binding sites 
reflect a steric blockage of or~e xtra base pair without 
direct binding, or even a quadruplet binding site for 
elsamicin. This might favour an extra hydrogen bridge 
involving the charged amino group of one of the sugar 
moieties and/or accor-~modate the extra methyl group 
of the neutral sugar (see Fig. 1). The low solubility of 
chartreusin does not allow the use of the hydroxyl radi- 
cal as a footprinting tool since the presence of DMSO 
will quench the reaction. It is well known that only 
drugs which are soluble in aqueous olutions have been 
successfully footprinted using hydroxyl radicals [18,19]. 
A deeper knowledge of the characteristics of the binding 
sites and the specific contacts between the DNA bases 
and the disaccharide moieties of these antibiotics will 
require the availability of crystallised structures. Our 
footprinting results suggest he use of oligonucleotides 
containing a 5'-CG-3' step for this purpose. 
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A. B. 
5'- CT AA(AAACCAI'k'~I'~'AT~T(ACAI'/AACO/ATA AA AATAGG~ATC~3' 
m ' 438" 8 J ' * 4ZgB 4318 432B 433B 
"21 l 
5'-CTAA~AAACCn~AITATCAT(ACA~AACUATAAAAATAGGC~ATC(I.-)' 
429B 43BB 131B 4329 4338 
5'-OGlIGGCC(rl'Imt C~TC'I'IC~AGAA~ CRTG'I'/'I'GA C~GC'gTATC~TCGP 3' 5' -CGA GGCCC'gI'TC G'r C"I'~CR AG~A~C~IT GI'I'T G nCAGC~RT CATCCP 3' 
. . . . . . , . . . 
'I)4B 43SB ~13r, g IB 2B 4341 435B ¢36B 18 28 
Fig. 6. Differential cleavage plot for the 102-mer fragment of pBR322 in the presence of chartreusin, 30 #M (A), and in the presence of elsamicin, 
15 #M (B). Other details as in legend to Fig. 4. 
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